Clinical investigation of a very low dosage oral contraceptive combination: 0-75 mg lynestrenol and 0-0375 mg ethinyl oestradiol.
A trial was carried out in 3 clinics to test the efficacy of and cycle control obtained with a very low dosage oral contraceptive combination of lynesternol (0.75 mg) and ethinyl oestradiol (0.0375 mg). A total of 134 healthy, fertile women, ages ranging from under 19 years to over 40 years, participated and completed 1144 treatment cycles. No pregnancies occurred. Then length of the treatment cycle compared to the cycle length before treatment was unchanged in 79.3% of cases. Withdrawal bleeding occurred in 93.1% of all treatment cycles, and in 78.9% of cases the duration of the withdrawal bleeding corresponded to that of the bleeding before treatment. The proportion of irregular bleeding in the first treatment cycle was 51.4% but by the 12th treatment cycle this was reduced to 12.5%. Side-effects, when they did occur, were very slight; existing complaints clearly decreased during the treatment.
D000293:Adolescent; D000328:Adult; D001941:Breast Diseases / Q000139:chemically induced; D003560:Cysts / Q000139:chemically induced; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008234:Lynestrenol / Q000008:administration & dosage* / Q000009:adverse effects
D004997:Ethinyl Estradiol; D008234:Lynestrenol